Fecal Transplant Noninferior to Vancomycin for Initial C. Diff Therapy
Randomized trial supports option that could aid antibiotic stewardship
Related Articles
Pharmalittle: We’re reading about a new FDA review program, proposed DTC ad changes, and more
And more pharmaceutical daily news updates.
Egocentric value maps of the near-body environment
Nature Neuroscience – Some neurons act like body-proximity sensors. The authors show that these neurons reflect the value of contacting or avoiding objects. Together, these…
A Free Method for Patient-Specific 3D-VR Anatomical Modeling for Presurgical Planning Using DICOM Images and Open-Source Software – Beyond the Abstract
Patient-Specific 3D-VR Anatomical Modeling, DICOM Images, Patient-Specific 3D-VR Anatomical Modeling for Presurgical Planning Using DICOM Images and Open-Source Software, PSMA PET/CT, 99mTc-PSMA-I&S, salvage pelvic lymph…
Why Teens with OSA Shouldn’t Be Treated Like Adults, with Binal Kancherla, MD
At SLEEP 2025, Kancherla emphasized the importance of using pediatric criteria to manage OSA in adolescents, warning that adult standards may overlook key developmental factors.
Patient Safety Network Papers Restored Amid Lawsuit From Doctors
The papers had been removed from the government site over terms like ‘transgender’ and ‘LGBTQ’
PRIMARY Score and Where it Plays a Role in Prostate Cancer Diagnosis “Presentation” – Michael Hofman
At the 2025 UCSF-UCLA PSMA Conference, Michael Hofman presents the PRIMARY score for PSMA PET in prostate cancer diagnosis. He explains how PSMA PET complements…
FDA Approves Once-Monthly Hereditary Angioedema Drug
New option for prophylaxis is the first to target the top of the HAE cascade
An Adolescent with Undiagnosed Inattentive-Type Attention… : AJN The American Journal of Nursing
and learning disorders. The lack of adequate pediatric mental health resources highlights the critical need for experienced nurses and NPs to play a pivotal role…
Eli Lilly to buy gene-editing biotech Verve for up to $1.3 billion
Eli Lilly said Tuesday that it will acquire Verve Therapeutics, a biotech developing gene-editing therapies for cardiovascular disease.
